Reviva Pharma's schizophrenia drug succeeds in late-stage study (updated)

Reviva Pharmaceuticals Holdings

30/10/2023 11:54

(Adds details throughout)
       Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings
 RVPH.O  said on Monday its lead experimental drug to treat
adults with schizophrenia helped reduce disease symptoms in a
late-stage study.
   Schizophrenia is a chronic mental disorder that causes
distortion in thoughts, hallucinations and feelings of fright
and paranoia.
        The drug, brilaroxazine, clocked a 10.1 point reduction,
compared to a placebo, in a medical scale used to measure the
severity of schizophrenia symptoms like delusions,
hallucinations and emotional withdrawal among others. 
  
        Brilaroxazine belongs to a class of drugs called
serotonin-dopamine signaling modulator which regulates the
levels of two chemical messengers in the brain, serotonin and
dopamine.  
  
         

 (Reporting by Mariam Sunny in Bengaluru; Editing by Savio
D'Souza)
 ((Mariam.ESunny@thomsonreuters.com;))